Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 11/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL894015 | 0.92 | TRPA1 (0.46) | LMNATRPA1 | |
| SCHEMBL10164566 | 0.90 | TRPA1 (0.41) | LMNATRPA1TP53MAPT | |
| SCHEMBL10164564 | 0.88 | THRB (0.38) | LMNAMEN1KMT2ATRPA1L3MBTL1 | |
| SCHEMBL10164627 | 0.88 | TRPA1 (0.42) | TRPA1TP53MAPT | |
| SCHEMBL10164510 | 0.87 | L3MBTL1 (0.57) | LMNAMEN1KMT2ATRPA1L3MBTL1 | |
| SCHEMBL10164519 | 0.86 | TRPA1 (0.41) | MEN1KMT2ATRPA1TP53POLB | |
| SCHEMBL10164574 | 0.85 | TSHR (0.47) | TRPA1TP53 | |
| SCHEMBL10164562 | 0.85 | TRPA1 (0.47) | LMNAMEN1KMT2ATRPA1L3MBTL1 | |
| SCHEMBL10164592 | 0.82 | TRPA1 (0.47) | TRPA1TP53 | |
| SCHEMBL10164502 | 0.82 | TRPA1 (0.44) | TRPA1TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120083474-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083474-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | TRPA1, TRPV1, TRPV2 | LMNA 4619/4885MEN1 4531/4885KMT2A 3371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.